On February 2, 2024, Bristol-Myers Squibb Company released its financial results for the fourth quarter of 2023 and the full year of 2023. The announcement highlighted a fourth-quarter revenue of $11.5 billion, with a GAAP EPS of $0.87 and a Non-GAAP EPS of $1.70. Full-year revenues reached $45.0 billion, with a GAAP EPS of $3.86 and a Non-GAAP EPS of $7.51. The company's in-line and new product portfolio revenues increased by 9% to $9.8 billion for the quarter and by 7% to $37.9 billion for the year. Bristol-Myers Squibb also reported on strategic acquisitions and collaborations aimed at strengthening its long-term growth profile, including the planned acquisitions of Karuna Therapeutics and RayzeBio, and a strategic collaboration with SystImmune. Additionally, the company completed the purchase of...Show More

On February 2, 2024, Bristol-Myers Squibb Company released its financial results for the fourth quarter of 2023 and the full year of 2023. The announcement highlighted a fourth-quarter revenue of $11.5 billion, with a GAAP EPS of $0.87 and a Non-GAAP EPS of $1.70. Full-year revenues reached $45.0 billion, with a GAAP EPS of $3.86 and a Non-GAAP EPS of $7.51. The company's in-line and new product portfolio revenues increased by 9% to $9.8 billion for the quarter and by 7% to $37.9 billion for the year. Bristol-Myers Squibb also reported on strategic acquisitions and collaborations aimed at strengthening its long-term growth profile, including the planned acquisitions of Karuna Therapeutics and RayzeBio, and a strategic collaboration with SystImmune. Additionally, the company completed the purchase of Mirati Therapeutics. Research pipeline advancements were noted, including the U.S. approval of Augtyro and FDA acceptance of sBLAs for Breyanzi in follicular lymphoma and mantle cell lymphoma for priority review. The company provided guidance for 2024, expecting revenues to increase by low single digits and projecting a Non-GAAP EPS range of $7.10 to $7.40, excluding the impact of pending transactions.